US 12,391,691 B2
Synthesis of key intermediate of KRAS G12C inhibitor compound
Andrew Thomas Parsons, Cambridge, MA (US); Brian McNeil Cochran, San Diego, CA (US); William Powazinik, IV, Thousand Oaks, CA (US); and Marc Anthony Caporini, Belmont, MA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Dec. 19, 2024, as Appl. No. 18/987,568.
Application 18/987,568 is a division of application No. 17/689,741, filed on Mar. 8, 2022.
Application 17/689,741 is a continuation of application No. 16/685,841, filed on Nov. 15, 2019, granted, now 11,299,491, issued on Apr. 12, 2022.
Claims priority of provisional application 62/768,802, filed on Nov. 16, 2018.
Prior Publication US 2025/0206735 A1, Jun. 26, 2025
Int. Cl. C07D 471/04 (2006.01); C07C 69/76 (2006.01); C07C 69/78 (2006.01); C07C 309/24 (2006.01)
CPC C07D 471/04 (2013.01) [C07C 69/76 (2013.01); C07C 309/24 (2013.01)] 14 Claims
 
1. A process for preparing a composition of Formula (4a):

OG Complex Work Unit Chemistry
comprising reacting a compound of Formula (4)

OG Complex Work Unit Chemistry
with a compound of Formula (B1)

OG Complex Work Unit Chemistry
in the presence of 2-methyltetrahydrofuran to form the composition of Formula (4a).